{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:14:34Z","timestamp":1783624474241,"version":"3.55.0"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Dopamine agonists (DAs) have been linked to valvular heart disease (VHD). Literature suggests worsening valvular regurgitation with usage of these drugs, although some reports have found no significant association. This systematic review and meta-analysis aimed to determine whether treatment with ergot-derived DAs is associated with an increased incidence of VHD or worsening of preexisting valvular regurgitation. A systematic review and meta-analysis was conducted by synthesising data from multiple observational studies and clinical trials, focusing on the effects of both ergot-derived and non-ergot DAs on the development of VHD. Inclusion criteria were patients diagnosed with Parkinson disease or hyperprolactinaemia treated with DAs. Baseline patient characteristics including sex, ethnicity, cardiovascular risk factors, dosage, and duration of treatment were evaluated. Pooled risk estimates were calculated using random-effects models. Among 47,270 patients from 33 observational studies, those on ergot-derived DAs had a higher rate of developing VHD (4.0% vs 1.1% in non-ergot DA users or controls). The pooled risk ratio of VHD was significantly elevated in patients treated with pergolide [risk ratios (RR) 2.29, 95% confidence interval (CI): 1.62\u20133.24], cabergoline (RR 1.68, 95% CI: 1.21\u20132.34), and bromocriptine (RR 1.52, 95% CI: 1.02\u20132.27). Compared to controls, ergot-derived DAs were associated with an increased risk for aortic (RR 2.75, 95% CI: 1.81\u20134.20), mitral (RR 1.70, 95% CI: 1.23\u20132.36), and tricuspid (RR 1.54, 95% CI: 1.08\u20132.20) regurgitation. Ergot-derived DAs are significantly associated with an increased risk of VHD. Close echocardiographic monitoring should be emphasised for patients receiving ergot-derived DAs, particularly those on long-term or high-dose therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/crd.0000000000001387","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:00:12Z","timestamp":1783623612000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Association Between Ergot-Derived Dopamine Agonists and Valvular Heart Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.1097","author":[{"given":"Amer","family":"Hammad","sequence":"first","affiliation":[{"name":"Internal Medicine Department, Banner \u2013 University Medical Center Tucson, Tucson, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhura","family":"Ananthaneni","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Pikeville Medical Center, Pikeville, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Own","family":"Khraisat","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Englewood Hospital and Medical Center, Englewood, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St. Joseph\u2019s University Medical Center, Paterson, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Munshi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, St. Joseph\u2019s University Medical Center, Paterson, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama","family":"Al-Ashqar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, MedStar Washington Hospital Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roma","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, St. Joseph\u2019s University Medical Center, Paterson, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pruthvi","family":"Goparaju","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Charleston Area Medical Center, Charleston, WV"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel Rahman","family":"Dajani","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St. Joseph\u2019s University Medical Center, Paterson, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fayez","family":"Shamoon","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, St. Joseph\u2019s University Medical Center, Paterson, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Vasudev","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, St. Joseph\u2019s University Medical Center, Paterson, NJ"},{"name":"Department of Structural Heart Disease, St. Joseph\u2019s University Medical Center, Paterson, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"R1-20260709","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: a review.","volume":"311","author":"Connolly","year":"2014","journal-title":"JAMA"},{"key":"R2-20260709","first-page":"725","article-title":"Diagnosis and treatment of prolactinomas.","volume":"46","author":"Molitch","year":"2017","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R3-20260709","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(04)15945-X","article-title":"Treatment with pergolide and valvular heart disease.","volume":"363","author":"Van Camp","year":"2004","journal-title":"Lancet"},{"key":"R4-20260709","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine.","volume":"337","author":"Connolly","year":"1997","journal-title":"N Engl J Med"},{"key":"R5-20260709","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation.","volume":"356","author":"Schade","year":"2007","journal-title":"N Engl J Med"},{"key":"R6-20260709","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp068265","article-title":"Drugs and valvular heart disease.","volume":"356","author":"Roth","year":"2007","journal-title":"N Engl J Med"},{"key":"R7-20260709","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease.","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"key":"R8-20260709","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0192623310378027","article-title":"Serotonin and heart valve disease\u2014the serotonin hypothesis revisited.","volume":"38","author":"Elangbam","year":"2010","journal-title":"Toxicol Pathol"},{"key":"R9-20260709","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"key":"R10-20260709","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.amjcard.2007.06.045","article-title":"Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease.","volume":"100","author":"Droogmans","year":"2007","journal-title":"Am J Cardiol"},{"key":"R11-20260709","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S1474-4422(07)70218-1","article-title":"Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson\u2019s disease.","volume":"6","author":"Antonini","year":"2007","journal-title":"Lancet Neurol"},{"key":"R12-20260709","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/cen.13940","article-title":"Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology.","volume":"90","author":"Steeds","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R13-20260709","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline.","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-20260709","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40263-015-0293-4","article-title":"Dopamine agonists and cardiac valve disease: a review of epidemiological evidence.","volume":"29","author":"Tran","year":"2015","journal-title":"CNS Drugs"},{"key":"R15-20260709","first-page":"980","article-title":"Dopamine agonists and the risk of valvular heart disease: a systematic review.","volume":"37","author":"Fleury","year":"2021","journal-title":"Can J Cardiol"},{"key":"R16-20260709","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R18-20260709","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2288-14-45","article-title":"Newcastle-Ottawa Scale: comparing reviewers\u2019 to authors\u2019 assessments.","volume":"14","author":"Lo","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"R19-20260709","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R20-20260709","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R21-20260709","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R22-20260709","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/mds.20887","article-title":"Valvular heart disease in Parkinson\u2019s disease vs. controls: an echocardiographic study.","volume":"21","author":"Peralta","year":"2006","journal-title":"Mov Disord"},{"key":"R23-20260709","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1212\/01.wnl.0000238508.68593.1d","article-title":"Long-term effects of dopamine agonists on cardiac valves.","volume":"67","author":"Yamamoto","year":"2006","journal-title":"Neurology"},{"key":"R24-20260709","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/archneur.64.12.1721","article-title":"Heart valve regurgitation, pergolide use, and Parkinson disease: an observational study and meta-analysis.","volume":"64","author":"Corvol","year":"2007","journal-title":"Arch Neurol"},{"key":"R25-20260709","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/mds.21225","article-title":"Valvular heart disease in Parkinson\u2019s disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.","volume":"22","author":"Junghanns","year":"2007","journal-title":"Mov Disord"},{"key":"R26-20260709","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clineuro.2007.01.011","article-title":"Assessment of valvulopathy in Parkinson\u2019s disease patients on pergolide and\/or cabergoline.","volume":"109","author":"Kenangil","year":"2007","journal-title":"Clin Neurol Neurosurg"},{"key":"R27-20260709","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/j.1742-1241.2008.01779.x","article-title":"Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia.","volume":"62","author":"Bogazzi","year":"2008","journal-title":"Int J Clin Pract"},{"key":"R28-20260709","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1210\/jc.2007-1403","article-title":"Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline.","volume":"93","author":"Colao","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R29-20260709","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00415-008-0839-1","article-title":"Valvular heart disease in patients with Parkinson\u2019s disease treated with pergolide. Course following treatment modifications.","volume":"255","author":"Dupuy","year":"2008","journal-title":"J Neurol"},{"key":"R30-20260709","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1210\/jc.2007-2658","article-title":"Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.","volume":"93","author":"Kars","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R31-20260709","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-08-0213","article-title":"Cabergoline and the risk of valvular lesions in endocrine disease.","volume":"159","author":"Lancellotti","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"R32-20260709","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/mds.22228","article-title":"Bromocriptine use and the risk of valvular heart disease.","volume":"24","author":"Tan","year":"2009","journal-title":"Mov Disord"},{"key":"R33-20260709","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11102-008-0134-2","article-title":"Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas.","volume":"12","author":"Vallette","year":"2009","journal-title":"Pituitary"},{"key":"R34-20260709","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1530\/EJE-08-0365","article-title":"Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease.","volume":"159","author":"Wakil","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"R35-20260709","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/mds.22036","article-title":"The frequency of cardiac valvular regurgitation in Parkinson\u2019s disease.","volume":"23","author":"Yamashiro","year":"2008","journal-title":"Mov Disord"},{"key":"R36-20260709","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2265.2008.03458.x","article-title":"Valvular heart disease and the use of cabergoline for the treatment of prolactinoma.","volume":"70","author":"Herring","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R37-20260709","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2265.2010.03827.x","article-title":"Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia.","volume":"73","author":"Tan","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R38-20260709","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11102-011-0339-7","article-title":"A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas.","volume":"15","author":"Boguszewski","year":"2012","journal-title":"Pituitary"},{"key":"R39-20260709","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2169\/internalmedicine.50.4344","article-title":"Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson\u2019s disease.","volume":"50","author":"Nakaoka","year":"2011","journal-title":"Intern Med"},{"key":"R40-20260709","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1530\/EJE-12-0121","article-title":"Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.","volume":"167","author":"Elenkova","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"R41-20260709","doi-asserted-by":"crossref","first-page":"E1714","DOI":"10.1210\/jc.2012-1833","article-title":"No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly.","volume":"97","author":"Maione","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R42-20260709","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/11594940-000000000-00000","article-title":"Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson\u2019s disease and hyperprolactinaemia: a multi-country, nested case-control study.","volume":"35","author":"Trifir\u00f2","year":"2012","journal-title":"Drug Saf"},{"key":"R43-20260709","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12020-016-1120-5","article-title":"Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.","volume":"55","author":"Vroonen","year":"2017","journal-title":"Endocrine"},{"key":"R44-20260709","first-page":"463","article-title":"Heart abnormalities in Parkinson patients after discontinuation or continuation of ergot-derived dopamine agonists: a treatment-blinded echocardiographic study.","volume":"18","author":"Rasmussen","year":"2009","journal-title":"J Heart Valve Dis"},{"key":"R45-20260709","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1186\/s12872-021-02439-y","article-title":"Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine.","volume":"21","author":"Clausen","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"R46-20260709","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1210\/clinem\/dgaa882","article-title":"Incidence of cabergoline-associated valvulopathy in primary care patients with prolactinoma using hard cardiac endpoints.","volume":"106","author":"Stiles","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"R47-20260709","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0140-6736(06)69208-8","article-title":"Burden of valvular heart diseases: a population-based study.","volume":"368","author":"Nkomo","year":"2006","journal-title":"Lancet"},{"key":"R48-20260709","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1755-5922.2010.00169.x","article-title":"Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.","volume":"29","author":"Zanettini","year":"2011","journal-title":"Cardiovasc Ther"},{"key":"R49-20260709","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2265.2011.04326.x","article-title":"Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study.","volume":"77","author":"Delgado","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R50-20260709","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1530\/EJE-13-0231","article-title":"Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.","volume":"169","author":"Auriemma","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"R51-20260709","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1210\/jc.2016-2224","article-title":"A follow-up study of the prevalence of valvular heart abnormalities in hyperprolactinemic patients treated with cabergoline.","volume":"101","author":"Drake","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R52-20260709","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12902-020-0507-8","article-title":"Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study.","volume":"20","author":"Budayr","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"R53-20260709","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00415-008-0839-1","article-title":"Valvular heart disease in Parkinson\u2019s disease patients treated with dopamine agonists: a clinical and echocardiographic study.","volume":"255","author":"Dupuy","year":"2008","journal-title":"J Neurol"},{"key":"R54-20260709","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1365-2796.2007.01874.x","article-title":"Dopamine agonist-induced valvulopathy: a prospective study.","volume":"263","author":"Rasmussen","year":"2008","journal-title":"J Intern Med"},{"key":"R55-20260709","first-page":"877","article-title":"Dopamine agonists and valvular heart disease: a prospective echocardiographic study.","volume":"81","author":"Vallette","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:00:18Z","timestamp":1783623618000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":54,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001387","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]}}}